MARKET

ABUS

ABUS

Arbutus Biopharm
NASDAQ
3.320
-0.190
-5.41%
Closed 18:06 05/06 EDT
OPEN
3.470
PREV CLOSE
3.510
HIGH
3.490
LOW
3.320
VOLUME
821.07K
TURNOVER
0
52 WEEK HIGH
4.725
52 WEEK LOW
2.700
MARKET CAP
635.71M
P/E (TTM)
-8.8134
1D
5D
1M
3M
1Y
5Y
1D
Arbutus's Imdusiran Plus VTP-300 And Low-Dose Nivolumab Achieve HBsAg Loss And Seroconversion In cHBV Patients, New Phase 2a Data Reveal At EASL 2025
Benzinga · 2h ago
Arbutus Biopharma Reports Positive Phase 2a Results for Imdusiran in Combination with VTP-300 and Low Dose Nivolumab in Chronic Hepatitis B Patients at EASL 2025
NASDAQ · 3h ago
ARBUTUS PRESENTS CLINICAL TRIAL DATA FROM ITS TWO HBV ASSETS, IMDUSIRAN AND AB-101, AT THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER (EASL) CONGRESS 2025
Reuters · 3h ago
Weekly Report: what happened at ABUS last week (0428-0502)?
Weekly Report · 1d ago
Arbutus Biopharma Corp <ABUS.OQ> expected to post a loss of 10 cents a share - Earnings Preview
Reuters · 04/28 11:41
Weekly Report: what happened at ABUS last week (0421-0425)?
Weekly Report · 04/28 09:16
Will Arbutus Biopharma (ABUS) Report Negative Q1 Earnings? What You Should Know
NASDAQ · 04/24 14:02
Arbutus Biopharma Showcases Promising Hepatitis B Treatments at EASL Congress 2025
TipRanks · 04/23 10:33
More
About ABUS
More
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious disease. The Company is developing imdusiran (AB-729), its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). Its HBV product pipeline includes Imdusiran and AB-101. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for. PD-L1 inhibitors complement its pipeline of agents and could potentially be a part of a combination therapy for the treatment of HBV by reawakening the immune system.
Recently
Symbol
Price
%Change

Webull offers Arbutus Biopharma Corp stock information, including NASDAQ: ABUS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ABUS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ABUS stock methods without spending real money on the virtual paper trading platform.